Camurus Ab

Thank you so much, and hello, everyone. I hope you all have had a good start of the year. Welcome to Canary's fourth quarter and full year results call for 2021. Next slide, please. So, as usual, before starting the presentation, please note our forward-looking statements, which are subject to a number of uncertainties, risks, and assumptions. Slide three, please. The agenda for today's call includes a summary of the full year 2021 results along with highlights from the fourth quarter. Then we will give an update on the commercial development, followed by progress in the R&D pipeline. We will end the call with some takeaways, a full year 2022 outlook, followed by Q&A. With me today in the call is Richard Jameson, our Chief Commercial Officer, and John Garay Alonso, our new CFO, who joined Cameras only two weeks ago. It's a great pleasure to welcome John to the team, and I would now like to give him the opportunity to introduce himself before continuing the presentation. John, please, the stage is yours.

Thanks a lot, Frederic, and good afternoon, everyone. Wish you all are doing well. My name is John Garay. I'm 48 years old, born in Spain. And as Fredrik has just said, I joined Camurus two weeks ago. Before that, I have worked 10 years at Baxter, where I initially joined as the vice president of finance for Europe, Middle East, and Africa in the renal division. And through the years, my recent position has been the European finance director for the medication delivery and pharmaceuticals divisions. I have been working closely with business acceleration, operating result improvement, business model analysis, and development opportunities, either organically or via M&A. And right now, I'm really thrilled to collaborate with Frederic and Camurus management team to continue growing and developing Camurus into a global corporation. Thanks a lot, everyone. Wish you all a nice day. And Frederic, back to you.

Thank you, John. And then we'll move over to slide five, please. So Cameros had made very significant progress in 2021, delivering strong financial and operational results in what was a difficult operating environment. As you can see in the graphs on the right-hand side, both revenue and operating results improved strongly versus previous year. Our total net revenue grew by 79% to 601 million SEK. with product sales increasing by 84% to 594 million SECs. The full year operational results was minus 111 million SECs, which is a 46% improvement compared to previous year. Our commercial teams continued to deliver strong results, which meant that we, for the fourth, tenth consecutive quarter, achieved double-digit sales growth. and continue to establish our position as market leader in long-acting treatment of opioid dependence across our territories. Hugadong is now available in 17 markets across Europe, Australia and the Middle East, with expansion continuing. We advanced our pipeline as well through successful lifecycle management and new approvals, a new program in registration phase and finished the year with three ongoing Phase III programs in rare diseases. So let's move in on the highlights of the fourth quarter. Slide five, please. Highlights of the quarter included accelerated duvidal sales in key markets, EMA acceptance of our regulatory submission for chronic pain, continued progress of our Phase III studies of CAMP 2029 and acromegaly, and first dosing in a phase three study of CAM-2029 for treatment of neuroendocrine tumors. On the partner side, Rhythm started a new phase three program for our weekly formulation of CET melanotype for treatment of genetic obesity disease. However, a strong quarter ended with the news in December that our U.S. scientists at Braeburn were issued with a new CRL public study. Aside from this, it was a very positive quarter where we continued building our business towards profitability while progressing the pipeline. With increasing revenues, a stable cash position, Camurus has a great foundation to continue to execute on our strategy for value creation through commercialization excellence, diversification, and a growing pipeline. With this, I will leave the word over to Richard for a commercial update. Slide six, please.